Benzinga's Top Analyst Calls From April 9, 2018

• Argus raises IQVIA Holdings Inc. IQV price target from $110 to $112, says contract research organizations will benefit from “steady biopharmaceutical funding and a healthy backlog”; Firm raises 2018 adj. EPS forecast to reflect Q4 earnings surprise and addition of new multi-year contracts.
• Wedbush upgrades Comerica Incorporated CMA to Outperform, says margin expansion, potential resumption of loan growth, and above average capital returns should drive EPS growth over next two years.
• Citi reiterates Buy rating on Monster Beverage Corp MNST and maintains U.S. Focus List status, citing “strong trends” in global energy drink category; “MNST continues to gain share globally, and still has plenty of runway ahead."
• Chardan raises Regenxbio Inc RGNX price target from $85 to $90 on news co.'s partner, AveXis, was bought by Novartis, believing this could support M&A interest in RGNX & suggesting "consensus is underestimating the impact of AVXS-101 royalites on Regenxbio."
• Cantor Fitzgerald double downgrades NewLink Genetics Corp NLNK after Incyte's failed trial of a therapy similar to NewLink’s indoximod.
• Loop Capital Markets upgrades Rent-A-Center, Inc. RCII from Sell to Hold and raises price target from $6 to $9 based on widespread media reports of multiple bids for the company; Firm says Q1 performance may indicate to potential acquirers that business has “bottomed,” making a deal more attractive.
• 'Best-In-Class' Bridgewater Bancshares Inc BWB has strong credit quality, 20 percent upside potential, DA Davidson says in bullish initiation.

See Also:

Benzinga's Top Upgrades, Downgrades For April 9, 2018

8 Biggest Price Target Changes For Monday